Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Net Income (2022 - 2025)

Historic Net Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$30.9 million.

  • Taysha Gene Therapies' Net Income fell 2962.42% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 1565.51%. This contributed to the annual value of -$84.6 million for FY2024, which is 1456.17% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Net Income is -$30.9 million, which was down 2962.42% from -$24.9 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Net Income ranged from a high of -$15.0 million in Q4 2023 and a low of -$55.1 million during Q4 2022
  • Moreover, its 4-year median value for Net Income was -$23.8 million (2024), whereas its average is -$26.7 million.
  • In the last 5 years, Taysha Gene Therapies' Net Income surged by 7269.39% in 2023 and then tumbled by 4336.02% in 2024.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Net Income stood at -$55.1 million in 2022, then soared by 72.69% to -$15.0 million in 2023, then dropped by 21.39% to -$18.3 million in 2024, then tumbled by 69.11% to -$30.9 million in 2025.
  • Its last three reported values are -$30.9 million in Q3 2025, -$24.9 million for Q2 2025, and -$20.1 million during Q1 2025.